# EDGAR Filing Document

**Accession Number:** 0001936258
**File Stem:** 0000000000-23-000172
**Filing Date:** 2023-1
**Character Count:** 9242
**Document Hash:** 1e4db31552632b5dec7538f2a9b0b339
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-000172.hdr.sgml**: 20230228

**ACCESSION NUMBER**: 0000000000-23-000172

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230105

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NewAmsterdam Pharma Co N.V.
- **CENTRAL INDEX KEY:** 0001936258
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** GOOIMEER 2-35
- **CITY:** NARRDEN
- **STATE:** P7
- **ZIP:** 1411 DC
- **BUSINESS PHONE:** 35 206 2971

**MAIL ADDRESS:**
- **STREET 1:** GOOIMEER 2-35
- **CITY:** NARRDEN
- **STATE:** P7
- **ZIP:** 1411 DC

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NewAmsterdam Pharma Co B.V.
- **DATE OF NAME CHANGE:** 20220701

## Text-Extract

```

United States securities and exchange commission logo

                                January 5, 2023

       Dr. Michael Davidson
       Chief Executive Officer
       NewAmsterdam Pharma Co N.V.
       Gooimeer 2-35
       1411 DC Naarden
       The Netherlands

                                                        Re: NewAmsterdam Pharma
Co N.V.
                                                            Registration
Statement on Form F-1
                                                            Filed December 20,
2022
                                                            File No. 333-268888

       Dear Dr. Michael Davidson:

              We have limited our review of your registration statement to
those issues we have
       addressed in our comments. In some of our comments, we may ask you to
provide us with
       information so we may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Registration Statement filed on December 20, 2022

       Cover Page

   1.                                                   For each of the
securities being registered for resale, disclose the price that the selling
                                                        securityholders paid
for such securities.
   2.                                                   Disclose the exercise
price of the warrants compared to the market price of the underlying
                                                        securities. If the
warrants are out the money, please disclose the likelihood that warrant
                                                        holders will not
exercise their warrants. Provide similar disclosure in the prospectus
                                                        summary, risk factors,
MD&A, and use of proceeds section and disclose that cash
                                                        proceeds associated
with the exercises of the warrants are dependent on the stock price.
   3.                                                   Highlight the
significant impact that resales covered by this registration statement could
 Dr. Michael Davidson
NewAmsterdam Pharma Co N.V.
January 5, 2023
Page 2
         have on the public trading price of your securities.
Management's Discussion and Analysis of Financial Condition and Results of
Operations
Overview, page 156

4.       Please expand your discussion here to reflect the fact that this
offering involves the
         potential sale of a substantial portion of shares for resale and
discuss how such sales could
         impact the market price of the company's common stock.
General

5.       Please revise your prospectus to highlight any differences in the
current trading price, the
         prices that the PIPE investors acquired their shares and warrants, and
the price that the
         public security holders acquired their shares and warrants. Disclose
that while the PIPE
         investors may experience a positive rate of return based on the
current trading price, the
         public securityholders may not experience a similar rate of return on
the securities they
         purchased due to differences in the purchase prices and the current
trading price. Please
         also disclose the potential profit the selling securityholders will
earn based on the current
         trading price. Lastly, please include appropriate risk factor
disclosure.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Cindy Polynice at 202-551-8707 or Joe McCann at
202-551-6262 with any
other questions.

FirstName LastNameDr. Michael Davidson                          Sincerely,
Comapany NameNewAmsterdam Pharma Co N.V.
                                                                Division of
Corporation Finance
January 5, 2023 Page 2                                          Office of Life
Sciences
FirstName LastName

```

### Attached PDF Documents

**Attachment 1:** `filename1`

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

January 5, 2023

Dr. Michael Davidson
Chief Executive Officer
NewAmsterdam Pharma Co N.V.
Gooimeer 2-35
1411 DC Naarden
The Netherlands

**Re: NewAmsterdam Pharma Co N.V.**
**Registration Statement on Form F-1**
**Filed December 20, 2022**
**File No. 333-268888**

Dear Dr. Michael Davidson:

We have limited our review of your registration statement to those issues we have addressed in our comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments.

Registration Statement filed on December 20, 2022

Cover Page

1. For each of the securities being registered for resale, disclose the price that the selling securityholders paid for such securities.
2. Disclose the exercise price of the warrants compared to the market price of the underlying securities. If the warrants are out the money, please disclose the likelihood that warrant holders will not exercise their warrants. Provide similar disclosure in the prospectus summary, risk factors, MD&A, and use of proceeds section and disclose that cash proceeds associated with the exercises of the warrants are dependent on the stock price.
3. Highlight the significant impact that resales covered by this registration statement could

Dr. Michael Davidson  
New Amsterdam Pharma Co N.V.  
January 5, 2023  
Page 2

have on the public trading price of your securities.

# Management's Discussion and Analysis of Financial Condition and Results of Operations  
Overview, page 156

4. Please expand your discussion here to reflect the fact that this offering involves the potential sale of a substantial portion of shares for resale and discuss how such sales could impact the market price of the company's common stock.

# General

5. Please revise your prospectus to highlight any differences in the current trading price, the prices that the PIPE investors acquired their shares and warrants, and the price that the public security holders acquired their shares and warrants. Disclose that while the PIPE investors may experience a positive rate of return based on the current trading price, the public securityholders may not experience a similar rate of return on the securities they purchased due to differences in the purchase prices and the current trading price. Please also disclose the potential profit the selling securityholders will earn based on the current trading price. Lastly, please include appropriate risk factor disclosure.

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.

Please contact Cindy Polynice at 202-551-8707 or Joe McCann at 202-551-6262 with any other questions.

Sincerely,

Division of Corporation Finance